SCBE In The News
Stanford Daily, 02/10/11
--Unclear patent policies make future of stem cell research murky
Though patents are meant to encourage innovation, broad stem cell patent protection could slow research in the field, according to a recent report by the Hinxton Group, a body of scientists and public policy experts who study the ethical and legal challenges surrounding stem cell research. Irving Weissman, the Virginia & D.K. Ludwig Professor for Clinical Investigation in Cancer Research and director of the Stanford Institute for Stem Cell Biology and Regenerative Medicine; bionegineering graduate student Blake Byers; and Christopher Scott, director of Stanford’s Program on Stem Cells and Society and a senior research scholar at the Stanford Center for Biomedical Ethics, are quoted in this article.
--Taboo or not? Reproductive technology and the changing family
A panel discussion Saturday addressed the societal implications of technologically assisted reproduction. The discussion followed a matinee performance of a play by Carl Djerrasi, inventor of the birth control pill and a professor emeritus of chemistry. William Hurlbut, consulting professor at the Stanford Institute for Neuro Innovation and Translational Neuroscience; Valerie Baker, assistant professor of obstetrics and gynecology and medical director of the Stanford Fertility and Reproductive Medicine Center; and Hank Greely, with the Stanford Center for Biomedical Ethics, were part of the panel moderated by Bruce Goldman, a science writer with the medical school's Office of Communication and Public Affairs.